K191144 is an FDA 510(k) clearance for the Cellvizio 100 Series System with Confocal Miniprobes. This device is classified as a Confocal Optical Imaging (Class II - Special Controls, product code OWN).
Submitted by Mauna Kea Technologies (Paris, FR). The FDA issued a Cleared decision on January 24, 2020, 269 days after receiving the submission on April 30, 2019.
This device falls under the General & Plastic Surgery FDA review panel. Regulated under 21 CFR 876.1500. Collection Of Light Signals For Visualization Of Cellular Microstructures..